Cara Therapeutics tried to misdirect investors away from the failure of its osteoarthritis pain pill by burying negative results from a mid-stage clinical trial in the middle of a press release issued Thursday night. The ploy didn’t work. Cara shares plunged, with the stock trading down 30 percent to $17.99 this morning.

The lesson here: Read those clinical trial press releases slowly and carefully! Don’t get bamboozled.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Another lesson in how companies spin is when they set the bar so low, i.e., calling it a “safety study,” then go p-hacking/cherry picking for something positive to report. Worse still are fudged data.

  • Not necessarily negative. The results show they are on the right track but need to try a higher dose. 5 mg dose compared to other meds is still low. Foolish downgrade IMO

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine